Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 32Gynecologic 8Genitourinary 6Thoracic 5Sarcoma 4Gastrointestinal 3Tumor-Agnostic 2Other solid neoplasm 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Neoplasms 2

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × ixabepilone × Tumor-Agnostic × Clear all
NCT00207090 2020-11-02

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

R-Pharm

Phase 1 Completed
19 enrolled 28 charts
Tumor-Agnostic

Neoplasms

NCT00422097 2016-03-10

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

R-Pharm

Phase 1 Completed
40 enrolled 25 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡